VEMONIS FEMI

This brand name is authorized in Poland

Active ingredients

The drug VEMONIS FEMI contains a combination of these active pharmaceutical ingredients (APIs):

1 Metamizole sodium
UNII VSU62Z74ON - METAMIZOLE SODIUM

Metamizole sodium is a pyrazolone derivative with analgesic, antipyretic and slight antiinflammatory and spasmolytic properties. It has the most potent analgesic effect of all the pyrazolone derivatives. As with other analgesics, its mechanism of action has not been elucidated in detail. It includes inhibition of prostaglandin synthesis (PGE1 and PGE2) and reversible inhibition of platelet aggregation. It inhibits cyclo-oxygenase and influences the effect of arachidonic acid.

Read about Metamizole sodium
2 Caffeine
UNII 3G6A5W338E - CAFFEINE

Caffeine is structurally related to the methylxanthines theophylline and theobromine. Caffeine’s main action is as a CNS stimulant.

Read about Caffeine
3 Drotaverine
UNII 24ZVH4C669 - DROTAVERINE HYDROCHLORIDE
Read about Drotaverine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
N02BB52 Metamizole sodium, combinations excl. psycholeptics N Nervous system → N02 Analgesics → N02B Other analgesics and antipyretics → N02BB Pyrazolones
Discover more medicines within N02BB52

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: PL Rejestru Produktรณw Leczniczych Identifier(s): 100413354

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.